Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.

MLA

Söderlund, Stina, et al. “Plasma Proteomics in CML Patients before and after Initiation of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity and Loss of Angiogenic Stimuli.” Leukemia Research, vol. 50, Nov. 2016, pp. 95–103. EBSCOhost, https://doi.org/10.1016/j.leukres.2016.09.019.

APA

Söderlund, S., Christiansson, L., Persson, I., Hjorth-Hansen, H., Richter, J., Simonsson, B., Mustjoki, S., Olsson-Strömberg, U., & Loskog, A. (2016). Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. Leukemia Research, 50, 95–103. https://doi.org/10.1016/j.leukres.2016.09.019

Chicago

Söderlund, Stina, Lisa Christiansson, Inger Persson, Henrik Hjorth-Hansen, Johan Richter, Bengt Simonsson, Satu Mustjoki, Ulla Olsson-Strömberg, and Angelica Loskog. 2016. “Plasma Proteomics in CML Patients before and after Initiation of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity and Loss of Angiogenic Stimuli.” Leukemia Research 50 (November): 95–103. doi:10.1016/j.leukres.2016.09.019.